DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* BIOALLIANCE PHARMA *


 

1997 - IDF
Paris
www.bioalliancepharma.com

 

Discovery, Drugs
(also Delivery, Drugs)
Key words: Cancer, HIV, Opportunistic infections
Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE's ans drug delivery improvements
Clients: Prescribers
bioalliance@bioalliancepharma.com

Age: 20 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Greciet (Judith) [Pharm.D., ex-Eisai, Wyeth, LFB, Zeneca, Pharmacia]
Oper.Dir.-COO:
Med.Dir.-CMO: Attali (Pierre) [M.D., M.Sc., ex-Synthelabo, Sanofi, OSMO (co-founder), Molecular Engines Laboratories, Urogene]
Sc.Dir.-CSO: Kayitalire (Louis) [M.D., Institut Gustave Roussy, ex-Eli Lilly, B.M.S., Cephalon]
Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young]
SalesMktg: Dupré (Florence)
BusDev:
Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public
Note : Financière de la Montagne (a company of family Besançon-Trébouta, previously holding Laboratoires Delagrange, part of Synthelabo, acquired by Sanofi) holds 10% of capital in December 2012

Turnover (M€) : 0.91 (2009), 1.1 (2008), 3.5 (2007)
Total funding (M€) : 107.6
Last funding (M€) : 16.6
Focus : Cancers
Position : Launch
Company confirm : none

 

History
DATEMILESTONETYPETIME
2013 .04 Registration : positive FDA approval for acyclovir Lauriad (Sitavig) in USA MKTG [16 years]
2012 .12 Registration : positive EMA approval for acyclovir Lauriad (Sitavig) in Europe MKTG [15 years]
2012 .07 Licensing-out of US commercialization rights for Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults, to US company Vestiq LICOUT [15 years]
2012 .01 Clinical trial (phase I) for AMEP biotherapy in the metastatic melanoma (beginning, ended October 2012) and grant of a European patent covering the product until 2022 CLIN [14 years]
2011 .11 Registration : orphan Drug designation by EMA for clonidine Lauriad in Europe CLIN [14 years]
2011 .07 Public offering : 16.6 M€, as a capital increase RFIN [14 years]
2011 .06 Nomination : Judith Greciet as CEO (previously COO), while Dominique Costantini, co-founder, born 1955, retires ORGN [14 years]
2011 .03 Clinical trial (phase II) for Livatag (doxorubicin Transdrug), positive on survival in advanced hepatocellular carcinoma patients CLIN [14 years]
2010 .09 Patent : granted on Lauriad (drug delivery for acyclovir), in Europe LEGAL [13 years]
2010 .04 Registration : positive US FDA approval for Oravig (Loramyc in EU) with US$ 20 Million milestone payment from Strativa Pharmaceuticals, the commercial partner in the US MKTG [13 years]
2010 .04 Licensing-out of European commercialization rights for Loramyc and Setofilm to Therabel (Belgium) in a € 48.5 Million deal LICOUT [13 years]
2009 .12 Clinical trial (phase II) for Clonidine Lauriad (beginning) in radiotherapy and chemotherapy-induced oral mucositis and clinical trial (phase I) for AMEP (beginning) in invasive melanoma CLIN [12 years]
2009 .10 Clinical trial (phase I) for Fentanyl Lauriad, slow-release central analgesic in cancer patients (beginning) CLIN [12 years]
2009 .04 Clinical trial planned, after first preclinical trial results on new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer CLIN [12 years]
2009 .04 Financing (no interest loan) : 6.3 M€, by OSEO Innovation, to support Cancer Anti-invasive Program (CAP) private-public consortium (with Oroxcell and Xentech) DEBT [12 years]
2009 .03 Licensing-out of Loramyc rights to SpeBio (2007) in Europe regained (withdrawn contract and legal suite) LICOUT [12 years]
2009 .02 Registration : submission to EMEA of ondansetron RapidFilm MKTG [11 years]
2008 .12 Management restructuring : 9 heads employee reduction, i.e. 12% of total headcounts ORGR [11 years]
2008 .09 Financing : capital investment by AGF Private Equity (over 5% of equity) RFIN [11 years]
2008 .08 Nomination : Pierre Morgon as COO, along Gilles Avenard (Pierre Morgon resigns in May 2009) ORGN [11 years]
2008 .05 Licensing-in of European rights of Ondansetron spray from NovaDel LICIN [11 years]
2008 .03 Company (as Laboratory BioAlliance Pharma) founded by Dominique Costantini for Marketing and Trade ORGF [11 years]
2007 .09 Launch of Loramyc on French market MKTG [10 years]
2007 .07 4th round-financing : 40.0 M€, led by Bryan, Garnier & Co, with international investors (private capital increase) RFIND [10 years]
2007 .03 Licensing-out of Loramyc to PAR pharmaceuticals in USA, in a deal valued 95 MUS$ (15 MUS$ initially, plus milestones) LICOUT [10 years]
2006 .10 Registration : obtained for Loramyc, in France MKTG [9 years]
2005 .12 Public offering : 30.0 M€, Alternext, Eurolist PBO [8 years]
2004 .08 3rd round-financing : 2.0 M€ (follow-up), by Siparex Ventures RFINC [7 years]
2003 .05 3rd round-financing : 10.0 M€, led by Auriga Partners RFINC [6 years]
2000 .05 2nd round-financing : 7.0 M€, by Technolife, ABN-Amro, Spef, and previous shareholders RFINB [3 years]
1999 .09 1st round-financing : 1.5 M€, by 3i, Capricorn Venture, and a business angel RFINA [2 years]
1997 .03 Company founded by Dominique Costantini and Gilles Avenard ORGF [0 year]

Actualisation / Updating: 19-Apr-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende